These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 16105641)

  • 21. Inotropic therapy of heart failure. Editorial comments on: Vasodilation and mechanoenergetic inefficiency dominates the effect of the "Ca2+ sensitizer" MCI-154 in intact pigs.
    Duncker DJ; Verdouw PD
    Scand Cardiovasc J; 2002 May; 36(3):131-5. PubMed ID: 12079634
    [No Abstract]   [Full Text] [Related]  

  • 22. Effect of levosimendan on right ventricular systolic and diastolic functions in patients with ischaemic heart failure.
    Duygu H; Ozerkan F; Zoghi M; Nalbantgil S; Yildiz A; Akilli A; Akin M; Nazli C; Ergene O
    Int J Clin Pract; 2008 Feb; 62(2):228-33. PubMed ID: 17949428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Inotropic agents in advanced and refractory heart failure].
    Mangiavacchi M; Gronda E
    Ital Heart J Suppl; 2003 Jan; 4(1):3-7. PubMed ID: 12690928
    [No Abstract]   [Full Text] [Related]  

  • 24. Levosimendan therapy in decompensated chronic heart failure: favourable haemodynamic and neurohormonal effects but for how long?
    Parissis JT; Farmakis D; Kremastinos DT
    Eur J Heart Fail; 2006 Mar; 8(2):215; author reply 218. PubMed ID: 16442844
    [No Abstract]   [Full Text] [Related]  

  • 25. The case for levosimendan.
    De Keulenaer BL
    Crit Care Resusc; 2008 Sep; 10(3):180. PubMed ID: 18798714
    [No Abstract]   [Full Text] [Related]  

  • 26. Effects of levosimendan on markers of kidney function in patients with acutely decompensated heart failure and renal impairment.
    Rafouli-Stergiou P; Parissis JT; Farmakis D; Bistola V; Frogoudaki A; Vasiliadis K; Ikonomidis I; Paraskevaidis I; Kremastinos D; Filippatos G; Lekakis J
    J Cardiovasc Med (Hagerstown); 2017 Oct; 18(10):771-773. PubMed ID: 25643197
    [No Abstract]   [Full Text] [Related]  

  • 27. Effects of levosimendan on right ventricular function in patients with advanced heart failure.
    Parissis JT; Paraskevaidis I; Bistola V; Farmakis D; Panou F; Kourea K; Nikolaou M; Filippatos G; Kremastinos D
    Am J Cardiol; 2006 Dec; 98(11):1489-92. PubMed ID: 17126656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Levosimendan: calcium sensitizer and inodilator.
    Milligan DJ; Fields AM
    Anesthesiol Clin; 2010 Dec; 28(4):753-60. PubMed ID: 21074750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The utility of levosimendan in the treatment of heart failure.
    Lehtonen L; Põder P
    Ann Med; 2007; 39(1):2-17. PubMed ID: 17364447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Positive inotropic effect of levosimendan is correlated to its stereoselective Ca2+-sensitizing effect but not to stereoselective phosphodiesterase inhibition.
    Kaheinen P; Pollesello P; Hertelendi Z; Borbély A; Szilágyi S; Nissinen E; Haikala H; Papp Z
    Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):74-8. PubMed ID: 16433895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
    Earl GL; Fitzpatrick JT
    Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Levosimendan: a new option in acute septic cardiac failure?
    Powell BP; De Keulenaer B
    Emerg Med Australas; 2007 Apr; 19(2):177; author reply 177-8. PubMed ID: 17448109
    [No Abstract]   [Full Text] [Related]  

  • 33. Levosimendan in regional myocardial ischemia.
    Pieske B
    Cardiovasc Drugs Ther; 2002 Sep; 16(5):379-81. PubMed ID: 12656119
    [No Abstract]   [Full Text] [Related]  

  • 34. Calcium sensitizer agents: a new class of inotropic agents in the treatment of decompensated heart failure.
    Perrone SV; Kaplinsky EJ
    Int J Cardiol; 2005 Sep; 103(3):248-55. PubMed ID: 16098385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Acute hemodynamic and clinical effects of a new inotropic agent, levosimendan, in patients with severe heart failure].
    Porcu M; Orrù P
    Ital Heart J Suppl; 2001 Feb; 2(2):205-6. PubMed ID: 11255888
    [No Abstract]   [Full Text] [Related]  

  • 36. New positive inotropic agents in the treatment of left ventricular dysfunction.
    De Luca L; Proietti P; Palombaro GL; Battagliese A; Celotto A; Bucciarelli Ducci C; Fedele F
    Ital Heart J; 2004 Jun; 5 Suppl 6():63S-67S. PubMed ID: 15185917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levosimendan in cardiac surgery: a unique drug for the treatment of perioperative left ventricular dysfunction or just another inodilator searching for a clinical application?
    Pagel PS
    Anesth Analg; 2007 Apr; 104(4):759-61. PubMed ID: 17377077
    [No Abstract]   [Full Text] [Related]  

  • 38. Levosimendan in heart failure after surgical repair of cardiac rupture.
    Torrado H; Ventura JL; Ruiz-Majoral A; Farrero E; Rodriguez-Castro D; Carrio ML; Miralles A
    Minerva Cardioangiol; 2009 Feb; 57(1):137-8. PubMed ID: 19202525
    [No Abstract]   [Full Text] [Related]  

  • 39. The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitiser, with cardiac troponin c.
    Sorsa T; Pollesello P; Solaro RJ
    Mol Cell Biochem; 2004 Nov; 266(1-2):87-107. PubMed ID: 15646030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: comparison with dobutamine and milrinone.
    Barraud D; Faivre V; Damy T; Welschbillig S; Gayat E; Heymes C; Payen D; Shah AM; Mebazaa A
    Crit Care Med; 2007 May; 35(5):1376-82. PubMed ID: 17414729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.